Yangmei Chen

Prof. Dr. Yangmei Chen


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in eClinicalMedicine
Verified
Journal Article
Open access
YCYankun Chen
Yankun Chen
WLWenze Li
Wenze Li
CLChenfei Lu
Chenfei Lu
XGXinxia Gao
Xinxia Gao
HSHuizhen Song
Huizhen Song
YCYangmei Chen
Yangmei Chen
Adjunctive newer antiseizure medications (ASMs) are being used in patients with treatment-resistant focal-onset seizures (FOS). An updated network meta-analysis (NMA) was necessary to compile evidence in this critical area. We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus from their inception until 17 January 2024, evaluating the efficacy, tolerability, and safety of rufinamide (RUF), brivaracetam (BRV), cenobamate (CNB), eslicarbazepine (ESL), lacosamide (LCM), retigabine (RTG), and perampanel (PER) as adjunctive treatments for FOS. Efficacy outcomes included seizure response and seizure freedom. Tolerability was assessed by discontinuation due to adverse events (AEs). Safety outcomes were evaluated based on the number of patients experiencing at least one AE and serious adverse events (SAEs). This review is registered with PROSPERO (CRD42023485130). A total of 29 studies involving 11,750 participants were included. For seizure response, all ASMs were significantly superior to placebo, with RTG ranking highest, followed by CNB. Considering dosage, CNB 400 mg/d was top-ranked, followed by RTG 1200 mg/d. For seizure freedom, BRV was highest-ranked, followed by CNB, with BRV 100 mg/d leading, followed by CNB 400 mg/d. Regarding tolerability, LCM 600 mg/d had the lowest ranking, followed by CNB 400 mg/d. For the safety outcome of AEs, ESL 1200 mg/d was ranked lowest, followed by CNB 400 mg/d. Regarding SAEs, LCM 400 mg/d was ranked lowest, followed by RTG 1200 mg/d. ASMs at different dosages have varying efficacy and tolerability profiles. We have provided hierarchical rankings of ASMs for efficacy and safety outcomes. Our findings offer the most comprehensive evidence available to inform patients, families, physicians, guideline developers, and policymakers about the choice of ASMs in patients with treatment-resistant FOS. None.

11 September 2019 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
JFJie Fu
Jie Fu
LPLilei Peng
Lilei Peng
WWWeijun Wang
Weijun Wang
HHHaiping He
Haiping He
SZShan Zeng
Shan Zeng
YCYangmei Chen
Yangmei Chen

1 January 2020 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
RLRong Li
Rong Li
MHMiaoqing He
Miaoqing He
BWBing Wu
Bing Wu
PZPeng Zhang
Peng Zhang
QZQinbin Zhang
Qinbin Zhang
YCYangmei Chen
Yangmei Chen
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are the predominant mediators of glutamate-induced excitatory neurotransmission. It is widely accepted that AMPA receptors are critical for the generation and spread of epileptic seizure activity. Dysfunction of AMPA receptors as a causal factor in patients with intractable epilepsy results in neurotransmission failure. Brain-specific serine/threonine-protein kinase 1 (SAD-B), a serine-threonine kinase specifically expressed in the brain, has been shown to regulate AMPA receptor-mediated neurotransmission through a presynaptic mechanism. In cultured rat hippocampal neurons, the overexpression of SAD-B significantly increases the frequency of miniature excitatory postsynaptic currents (mEPSCs). Here, we showed that SAD-B downregulation exerted antiepileptic activity by regulating AMPA receptors in patients with temporal lobe epilepsy (TLE) and in the pentylenetetrazol (PTZ)-induced epileptic model. We first used immunoblotting and immunohistochemistry analysis to demonstrate that SAD-B expression was increased in the epileptic rat brain. Subsequently, to explore the function of SAD-B in epilepsy, we used siRNA to knock down SAD-B protein and observed behavior after PTZ-induced seizures. We found that SAD-B downregulation attenuated seizure severity and susceptibility in the PTZ-induced epileptic model. Furthermore, we showed that the antiepileptic effect of SAD-B downregulation on PTZ-induced seizure was abolished by CNQX (an AMPA receptor inhibitor), suggesting that SAD-B modulated epileptic seizure by regulating AMPA receptors in the brain. Taken together, these findings suggest that SAD-B may be a potential and novel therapeutic target to limit epileptic seizures.

21 May 2020 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
JYJuan Yang
Juan Yang
QJQian Jiang
Qian Jiang
XYXinyuan Yu
Xinyuan Yu
TXTao Xu
Tao Xu
YWYou Wang
You Wang
YCYangmei Chen
Yangmei Chen
Introduction: A large amount of literature has indicated that excitatory synaptic transmission plays a crucial role in epilepsy, but the detailed pathogenesis still needs to be clarified.Methods: In the present study, we used samples from patients with temporal lobe epilepsy, pentylenetetrazole‐kindled mice, and Mg2+‐free‐induced epileptic cultured hippocampal neurons to detect the expression pattern of STK24. Then, the whole‐cell recording was carried out after STK24 overexpression in the Mg2+‐free‐induced epileptic cultured hippocampal neurons. In addition, coimmunoprecipitation was performed to detect the association between endogenous STK24 and main subunits of NMDARs and AMPARs in the hippocampus of PTZ‐kindled mice.Results: Here, we reported that STK24 was specifically located in epileptic neurons of human and pentylenetetrazole‐kindled mice. Meanwhile, the expression of STK24 was significantly down‐regulated in these samples which are mentioned above. Besides, we found that the amplitude of miniature excitatory postsynaptic currents was increased in STK24 overexpressed epileptic hippocampal cultured neurons, which means the excitatory synaptic transmission was changed. Moreover, the coimmunoprecipitation, which further supported the previous experiment, indicated an association between STK24 and the subunits of the NMDA receptor.Conclusion: These findings expand our understanding of how STK24 involved in the excitatory synaptic transmission in epilepsy and lay a foundation for exploring the possibility of STK24 as a drug target.

9 May 2024 in European Radiology
Verified
Journal Article
Closed access
PDF file
CGChen Gong
Chen Gong
LHLiping Huang
Liping Huang
JHJiacheng Huang
Jiacheng Huang
LCLiyuan Chen
Liyuan Chen
WKWeilin Kong
Weilin Kong
CLChang Liu
Chang Liu

14 March 2025 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
LHLiping Huang
Liping Huang
SJShuyu Jiang
Shuyu Jiang
CGChen Gong
Chen Gong
GWGang Wu
Gang Wu
JGJing Guo
Jing Guo
YCYangmei Chen
Yangmei Chen